Skip to content
BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

BioAtla, Inc. BCAB

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$-59.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 7-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2024 · ROE -164.3%
-50%-100%-150%
201920222025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks

Total assetsUSD 13.8M
EquityUSD -36.2M
CashUSD 7.1M
Current ratio0.37×

Equity funds -262% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BCAB, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B◌◌◌◌0.0◌◌
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0
Income tax $B0.00.00.00.00.00.0◌
Net income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0
EPS, diluted $−1.01−1.44−2.58−2.74−2.76−3.19◌
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %—−164.3−98.4−54.4−45.3——
Shares out B0.060.000.000.000.000.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure in 25 reconciliationsAUDITED

Reconciled in 6 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image